A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients

Brief description of study

This phase I study is designed to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 in healthy participants and initial efficacy in CHB patients. A Safety Review Committee (SRC) will perform ongoing reviews of safety and tolerability based on available study data collected throughout the study. The study will be conducted in four Parts:

  • Part A: SAD in healthy participants (double blinded)
  • Part B: MD in healthy participants (double blinded)
  • Part C: MD in CHB patients (open label)
  • Part D: MD in CHB patients (double blinded; multiple sites)


Clinical Study Identifier: s23-00843
Principal Investigator: Ira M. Jacobson.
Other Investigator: Monique Julia Carasso.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.